Matches in Wikidata for { <http://www.wikidata.org/entity/Q98937555> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q98937555 description "article scientifique publié en 2020" @default.
- Q98937555 description "artículu científicu espublizáu en setiembre de 2020" @default.
- Q98937555 description "scientific article published on 02 September 2020" @default.
- Q98937555 description "wetenschappelijk artikel" @default.
- Q98937555 description "наукова стаття, опублікована 2 вересня 2020" @default.
- Q98937555 name "A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial" @default.
- Q98937555 name "A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial" @default.
- Q98937555 type Item @default.
- Q98937555 label "A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial" @default.
- Q98937555 label "A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial" @default.
- Q98937555 prefLabel "A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial" @default.
- Q98937555 prefLabel "A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial" @default.
- Q98937555 P1433 Q98937555-0D15C6E2-7F74-40B7-A67D-6B0A29CB52E4 @default.
- Q98937555 P1476 Q98937555-9EC6D2C4-AE54-4232-9609-980E08D33860 @default.
- Q98937555 P2093 Q98937555-0E8E8FB0-FF2C-4278-99C1-C968708461D7 @default.
- Q98937555 P2093 Q98937555-0FB2961F-60B0-4430-A035-15F53984AC80 @default.
- Q98937555 P2093 Q98937555-14CF3ED7-E778-4593-A6CD-2F00591D80A8 @default.
- Q98937555 P2093 Q98937555-289A3D30-BF04-4D70-AA4B-965995984E25 @default.
- Q98937555 P2093 Q98937555-42751CE9-B97D-497E-A19E-E2AA65E1E8AA @default.
- Q98937555 P2093 Q98937555-5607EB72-D8EF-4273-83DD-A67F39B14D94 @default.
- Q98937555 P2093 Q98937555-6FC10B11-1108-4EF8-BE6E-AF1F88ADD5E7 @default.
- Q98937555 P2093 Q98937555-811279ED-4BD2-4F48-A06F-2B47E36DB2F6 @default.
- Q98937555 P2093 Q98937555-81C61163-1952-43EB-B991-CCEE8883E179 @default.
- Q98937555 P2093 Q98937555-8D325E55-8E38-4899-8E2E-9B3C89609ACB @default.
- Q98937555 P2093 Q98937555-DA5CF24A-DC5B-4178-B8FF-9DC12B4951C5 @default.
- Q98937555 P2093 Q98937555-E3109C98-1497-42F4-99E8-CF11C71E12AD @default.
- Q98937555 P31 Q98937555-B4422AA7-A34A-41FA-962B-55C1F4145DAD @default.
- Q98937555 P356 Q98937555-C84B8EAF-9754-4F80-B2CD-5DFB4870CC9F @default.
- Q98937555 P50 Q98937555-078B37AF-630A-48A4-8746-363D700A7748 @default.
- Q98937555 P50 Q98937555-0B40F7A2-EE1B-40E4-897E-295EAEF25D5D @default.
- Q98937555 P50 Q98937555-11C9AEED-8A67-426C-B606-1563868F068F @default.
- Q98937555 P50 Q98937555-1CBA01D1-AF60-4B70-8637-DC3D86C28831 @default.
- Q98937555 P50 Q98937555-279B624C-DA22-432A-AD34-0985A1E7A10E @default.
- Q98937555 P50 Q98937555-3C84C428-B409-4AF7-9653-B49603B16D06 @default.
- Q98937555 P50 Q98937555-E82AB3FA-D6CE-48CF-8AF8-7B5E941E5D9C @default.
- Q98937555 P50 Q98937555-EDC18645-B884-4C4C-BDAC-5918D309E28D @default.
- Q98937555 P577 Q98937555-1E04CBE5-3C1E-4FC8-813C-1C4C8D71B421 @default.
- Q98937555 P698 Q98937555-C9AA7951-5C8F-43BE-A924-630E49987BCC @default.
- Q98937555 P921 Q98937555-4446EC6D-0A51-45CA-8E3F-D08BED805630 @default.
- Q98937555 P932 Q98937555-14057D79-BD0F-4175-B30F-42E347BD84A6 @default.
- Q98937555 P356 BJD.19509 @default.
- Q98937555 P698 32880909 @default.
- Q98937555 P1433 Q4970191 @default.
- Q98937555 P1476 "A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial" @default.
- Q98937555 P2093 "B Zhu" @default.
- Q98937555 P2093 "C E M Griffiths" @default.
- Q98937555 P2093 "C Leonardi" @default.
- Q98937555 P2093 "G Gallo" @default.
- Q98937555 P2093 "H Elmaraghy" @default.
- Q98937555 P2093 "J J Crowley" @default.
- Q98937555 P2093 "L C Guenther" @default.
- Q98937555 P2093 "L Renda" @default.
- Q98937555 P2093 "R G Langley" @default.
- Q98937555 P2093 "R G Lima" @default.
- Q98937555 P2093 "S Y Park" @default.
- Q98937555 P2093 "Y Tada" @default.
- Q98937555 P31 Q13442814 @default.
- Q98937555 P356 "10.1111/BJD.19509" @default.
- Q98937555 P50 Q117272096 @default.
- Q98937555 P50 Q54269356 @default.
- Q98937555 P50 Q54572621 @default.
- Q98937555 P50 Q56826450 @default.
- Q98937555 P50 Q57038615 @default.
- Q98937555 P50 Q57262393 @default.
- Q98937555 P50 Q89492015 @default.
- Q98937555 P50 Q98937553 @default.
- Q98937555 P577 "2020-09-02T00:00:00Z" @default.
- Q98937555 P698 "32880909" @default.
- Q98937555 P921 Q10355321 @default.
- Q98937555 P932 "8246960" @default.